Carisma Therapeutics, Inc. (NASDAQ:CARM) Sees Significant Decrease in Short Interest

Carisma Therapeutics, Inc. (NASDAQ:CARM) was the recipient of a significant decline in short interest during the month of October. As of October 31st, there was short interest totalling 857,500 shares, a decline of 18.3% from the October 15th total of 1,050,000 shares. Approximately 4.0% of the shares of the company are sold short. Based on an average daily trading volume, of 146,200 shares, the days-to-cover ratio is presently 5.9 days.

Wall Street Analyst Weigh In

Separately, EF Hutton Acquisition Co. I upgraded Carisma Therapeutics to a “strong-buy” rating in a research note on Wednesday, October 30th.

Institutional Trading of Carisma Therapeutics

Several large investors have recently modified their holdings of the stock. Vanguard Group Inc. grew its stake in Carisma Therapeutics by 0.7% during the first quarter. Vanguard Group Inc. now owns 1,579,961 shares of the company’s stock worth $3,587,000 after buying an additional 11,200 shares in the last quarter. Wexford Capital LP lifted its holdings in shares of Carisma Therapeutics by 75.5% during the 3rd quarter. Wexford Capital LP now owns 34,861 shares of the company’s stock worth $34,000 after acquiring an additional 15,000 shares during the period. Point72 Asia Singapore Pte. Ltd. acquired a new stake in shares of Carisma Therapeutics during the 2nd quarter worth approximately $40,000. Finally, Barclays PLC increased its stake in Carisma Therapeutics by 3,661,933.3% in the third quarter. Barclays PLC now owns 549,305 shares of the company’s stock valued at $539,000 after acquiring an additional 549,290 shares during the last quarter. 44.27% of the stock is owned by institutional investors and hedge funds.

Carisma Therapeutics Stock Performance

NASDAQ CARM traded down $0.06 on Friday, reaching $0.88. The stock had a trading volume of 237,958 shares, compared to its average volume of 341,220. The company has a debt-to-equity ratio of 1.39, a current ratio of 3.23 and a quick ratio of 3.23. The company has a market cap of $36.87 million, a P/E ratio of -0.57 and a beta of 1.49. The firm has a fifty day moving average of $0.98 and a two-hundred day moving average of $1.13. Carisma Therapeutics has a 1-year low of $0.80 and a 1-year high of $3.16.

Carisma Therapeutics (NASDAQ:CARM) last released its quarterly earnings results on Thursday, November 7th. The company reported ($0.31) EPS for the quarter, meeting the consensus estimate of ($0.31). Carisma Therapeutics had a negative net margin of 314.78% and a negative return on equity of 957.20%. The business had revenue of $3.39 million for the quarter. On average, equities research analysts anticipate that Carisma Therapeutics will post -1.33 EPS for the current year.

Carisma Therapeutics Company Profile

Carisma Therapeutics, Inc, a clinical-stage cell therapy company, focuses on discovering and developing immunotherapies to treat cancer and other serious diseases in the United States. The company's ex vivo CAR-M cell therapies include CT-0508, a CAR-macrophage, which is in Phase 1 clinical trial to treat solid tumors; CT-0525, a CAR-monocyte that is in Phase 1 clinical trial to treat solid tumors; and CT-1119, a mesothelin-targeted CAR-Monocyte that is in pre-clinical stage to treat patients with advanced mesothelin-positive solid tumors, including lung cancer, mesothelioma, pancreatic cancer, ovarian cancer, and others.